Megan is an assistant editor at MJH. She joined the company in 2022 after graduating from UMass Amherst with majors in communication and english. When not at work, Megan enjoys fishing, spending time with her twin sister, and listening to Taylor Swift on repeat. Email Megan at mhollasch@onclive.com
Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers
March 30th 2023To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.
Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical Practice
March 7th 2023Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.
Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUC
January 13th 2023Neoadjuvant treatment with gemcitabine and split-dose cisplatin followed by surgical resection and lymph node dissection proved to be effective and well-tolerated for patients with high-risk upper tract urothelial carcinoma.
Ovarian Suppression Treatment Is Rare for Premenopausal Women with HR+/HER2+ Breast Cancer
December 12th 2022In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.